JPM vs PFE: Which Is the Better Buy?
Side-by-side comparison of JPMorgan Chase & Co. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-18.
JPMorgan Chase & Co. · Financial Services
$350.13
+26.9% upside to fair value
Med Conviction
Grade A-
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
JPM has more upside to fair value
(+26.9%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
JPM |
PFE |
| Current Price |
$350.13 |
$27.64 |
| Fair Value Estimate |
$444.48 |
$30.94 |
| Upside to Fair Value |
+26.9%
|
+12.0%
|
| Market Cap |
$938.2B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
20.0x
|
17.4x
|
| Price / Sales |
3.1x
|
2.5x
|
| Price / FCF |
—
|
14.3x
|
| Revenue Growth YoY |
+17.9%
|
+2.6%
|
| Gross Margin |
62.6%
|
71.3%
|
| Operating Margin |
28.2%
|
25.1%
|
| Return on Equity |
17.8%
|
4.9%
|
| Dividend Yield |
1.71% |
6.22% |
| FCF Yield |
—
|
6.97%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
JPMorgan Chase is a diversified global bank spanning consumer banking, cards, payments, commercial banking, investment banking, markets, treasury services, and asset and wealth management, with an unusually high-quality franchise supported by funding scale, distribution, leading market positions and cross-selling across 86.6 million U.S. consumers and more than 90% of Fortune 500 companies. Busin…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
JPM |
PFE |
| Zone Low |
$333.36 |
$23.21 |
| Zone High |
$377.81 |
$26.30 |
| In Buy Zone? |
Yes
|
No
|